Showing results (351-360 of 387) with videos related to

Sort By:
Pageof 39
Mayo Clinic Proceedings|August 12, 2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMartha Q Lacy, Angela Dispenzieri, Morie A Gertz, et al.
British Journal of Haematology|August 9, 2017
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemiaJonas Paludo, Jithma P Abeykoon, Shaji Kumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 7, 2017
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell LymphomaMyron S Czuczman, Marek Trněný, Andrew Davies, et al.
American Journal of Hematology|July 29, 2016
Early event status informs subsequent outcome in newly diagnosed follicular lymphomaMatthew J Maurer, Emmanuel Bachy, Hervé Ghesquières, et al.
American Journal of Hematology|September 3, 2025
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed TherapiesSuheil Albert Atallah-Yunes, Chijioke C Nze, Rebecca L King, et al.
Annals of Hematology|April 4, 2018
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemiaJonas Paludo, Jithma P Abeykoon, Amanda Shreders, et al.
Blood|July 5, 2011
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomasThomas E Witzig, Hui Tang, Ivana N M Micallef, et al.
Blood|October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomibShaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 23, 2021
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell LymphomaGrzegorz S Nowakowski, Annalisa Chiappella, Randy D Gascoyne, et al.
Blood|January 24, 2004
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control studyAngela Dispenzieri, Robert A Kyle, Martha Q Lacy, et al.
Pageof 39